Login to Your Account

Versicor Plans Anidulafungin Esophageal Candidiasis NDA

By Aaron Lorenzo

Wednesday, March 19, 2003
With positive Phase III data in hand, Versicor Inc. reiterated plans to file a new drug application by the end of next month for its lead candidate, anidulafungin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription